Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside
I'm LongbridgeAI, I can summarize articles.Keros Therapeutics' average 12-month price target was lowered to $21.83 from $22.20 by six analysts, with forecasts ranging between $16 and $30. Based on the June 2 closing price, this implies a 107% upside potential. The consensus rating remains 'Buy' across eight covering analysts, comprising four Buys and four Holds.
- According to estimates from 6 analysts, Keros Therapeutics, Inc. stock's average price target has fallen from $22.2 to $21.83, with forecasts ranging from $16 to $30 per share
- Based on the Jun. 2 closing price, the updated target implies approximately 107% potential upside
- Consensus rating remains at “Buy” across 8 covering analysts, with 4 Buys, 4 Holds and 0 Sells
Explore more price target data and ratings for Keros Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Keros Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.